MA29736B1 - Preparations liquides - Google Patents

Preparations liquides

Info

Publication number
MA29736B1
MA29736B1 MA30632A MA30632A MA29736B1 MA 29736 B1 MA29736 B1 MA 29736B1 MA 30632 A MA30632 A MA 30632A MA 30632 A MA30632 A MA 30632A MA 29736 B1 MA29736 B1 MA 29736B1
Authority
MA
Morocco
Prior art keywords
liquid preparations
avalate
diol
glycerin
propane
Prior art date
Application number
MA30632A
Other languages
English (en)
Inventor
Vivian Georgousis
Wei-Qin Tong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37734410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29736(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29736B1 publication Critical patent/MA29736B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'INVENTION CONCERNE UN CONCENTRÉ DESTINÉ À ÊTRE DILUÉ, COMPRENANT UN AGONISTE DU RÉCEPTEUR S1P OU UN DE SES SELS DE QUALITÉ PHARMACEUTIQUE, DU PROPANE-1,2-DIOL ET ÉVENTUELLEMENT DE LA GLYCÉRINE. CETTE PRÉPARATION CONVIENT AUX PATIENT AYANT DE LA DIFFICULTÉ À AVALER
MA30632A 2005-08-09 2008-02-08 Preparations liquides MA29736B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70682005P 2005-08-09 2005-08-09

Publications (1)

Publication Number Publication Date
MA29736B1 true MA29736B1 (fr) 2008-09-01

Family

ID=37734410

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30632A MA29736B1 (fr) 2005-08-09 2008-02-08 Preparations liquides

Country Status (23)

Country Link
US (4) US20080194526A1 (fr)
EP (1) EP1915130B1 (fr)
JP (1) JP5068755B2 (fr)
KR (1) KR101473494B1 (fr)
CN (1) CN101237852B (fr)
AR (1) AR056020A1 (fr)
AU (1) AU2006280138B2 (fr)
BR (1) BRPI0615009A2 (fr)
CA (1) CA2618018C (fr)
EC (1) ECSP088165A (fr)
GT (1) GT200600350A (fr)
IL (1) IL188915A0 (fr)
MA (1) MA29736B1 (fr)
MX (1) MX2008001967A (fr)
MY (1) MY145111A (fr)
NO (1) NO20081218L (fr)
NZ (2) NZ565696A (fr)
PE (2) PE20070337A1 (fr)
RU (2) RU2428180C2 (fr)
TN (1) TNSN08061A1 (fr)
TW (1) TWI317289B (fr)
WO (1) WO2007021666A2 (fr)
ZA (1) ZA200800640B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384749A1 (fr) * 2004-11-29 2011-11-09 Novartis AG Posologie d'un agoniste du récepteur S1P
EP2623113B1 (fr) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Composé pour l'inhibition d'enzymes
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
CA2701778C (fr) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Inhibiteurs de protease epoxy-cetone peptidique cristalline, et synthese de ceto-epoxydes d'acides amines
WO2009048993A2 (fr) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)
WO2009155475A1 (fr) * 2008-06-20 2009-12-23 Novartis Ag Compositions pédiatriques pour le traitement de la sclérose en plaques
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
AU2009327405A1 (en) * 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
HRP20131106T1 (hr) * 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
RU2011129229A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новые соли
MX2011008876A (es) * 2009-02-24 2011-09-21 Novartis Ag Metabolitos analogos de ceramida.
US20100243087A1 (en) * 2009-03-03 2010-09-30 Millipore Corporation System and pump apparatus for processing fluid samples
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (fr) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Utilisation de peptides epoxycetones pour la suppression de la metastase
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2014011695A2 (fr) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP3027174B1 (fr) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Compositions pharmaceutiques à base de fingolimod
WO2016042493A1 (fr) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
WO2016135644A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
ES3024636T3 (en) 2017-09-27 2025-06-04 Novartis Ag Parenteral formulation comprising siponimod
WO2019064212A1 (fr) 2017-09-29 2019-04-04 Novartis Ag Schéma posologique de siponimod
AU2018343239A1 (en) 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
WO2021214717A1 (fr) 2020-04-23 2021-10-28 Novartis Ag Schéma posologique pour l'utilisation de siponimod pour le traitement du syndrome de détresse respiratoire aiguë
WO2026120139A1 (fr) 2024-12-07 2026-06-11 Azurity Pharmaceuticals Ireland Limited Compositions comprenant du fingolimod ou un sel de celui-ci

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
DE19645549A1 (de) * 1996-11-05 1998-05-07 Bayer Ag Verfahren zur Herstellung von 2-Methyl-2,4-diaminopentan
ES2240868T3 (es) * 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
US6727283B2 (en) * 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
JPWO2003020313A1 (ja) * 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
JP4152884B2 (ja) * 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
KR100913269B1 (ko) * 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
JP5227492B2 (ja) * 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるｅｄｇレセプター結合剤の使用
WO2005032465A2 (fr) * 2003-10-01 2005-04-14 Merck & Co., Inc. 1,2,4-oxadiazoles substitues 3,5-aryle, heteroaryle ou cycloalkyle servant d'agonistes du recepteur s1p

Also Published As

Publication number Publication date
BRPI0615009A2 (pt) 2011-05-03
US20120328664A1 (en) 2012-12-27
AU2006280138A1 (en) 2007-02-22
AU2006280138B2 (en) 2010-03-04
CA2618018C (fr) 2016-05-31
GT200600350A (es) 2007-03-28
CA2618018A1 (fr) 2007-02-22
ECSP088165A (es) 2008-03-26
ZA200800640B (en) 2008-12-31
EP1915130A2 (fr) 2008-04-30
MY145111A (en) 2011-12-30
MX2008001967A (es) 2008-03-26
CN101237852A (zh) 2008-08-06
TNSN08061A1 (en) 2009-07-14
PE20070337A1 (es) 2007-04-18
AR056020A1 (es) 2007-09-12
HK1123188A1 (en) 2009-06-12
CN101237852B (zh) 2011-01-26
RU2011106364A (ru) 2012-08-27
WO2007021666A2 (fr) 2007-02-22
KR101473494B1 (ko) 2014-12-16
RU2470631C2 (ru) 2012-12-27
IL188915A0 (en) 2008-04-13
US20160030572A1 (en) 2016-02-04
NZ565696A (en) 2011-06-30
KR20080035608A (ko) 2008-04-23
TWI317289B (en) 2009-11-21
TW200738277A (en) 2007-10-16
EP1915130B1 (fr) 2016-07-13
RU2008108887A (ru) 2009-09-20
JP5068755B2 (ja) 2012-11-07
US20140179636A1 (en) 2014-06-26
NZ593121A (en) 2012-09-28
JP2009504653A (ja) 2009-02-05
NO20081218L (no) 2008-04-29
PE20100149A1 (es) 2010-03-24
US20080194526A1 (en) 2008-08-14
RU2428180C2 (ru) 2011-09-10
WO2007021666A3 (fr) 2007-05-31
US20150080347A9 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
Correll et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial
Deeks Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection
McMahon et al. Treatment of premature ejaculation in the Asia‐Pacific region: Results from a phase III double‐blind, parallel‐group study of dapoxetine
ECSP088165A (es) Formulaciones liquidas
WO2006034022A3 (fr) Guide de sonde utilise avec des systemes d'imagerie medicaux
MA35662B1 (fr) Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation
WO2002060316A3 (fr) Systeme de guidage d'instruments medicaux a radiolocalisation en stereo
BRPI0719142A8 (pt) Sistema e método para formação de imagem de tecido de próstata em uma estrutura anatômica
Shimizu et al. Atypical fungal vertebral osteomyelitis in a tsunami survivor of the Great East Japan Earthquake
Krishna et al. Validation of sexual functioning questionnaire in Indian patients
MA31507B1 (fr) Solutions pharmaceutiques orales contenant de la telbivudine
Rao et al. Disseminated blastomycosis in a child with a brief review of the Indian literature
Martinez-Diaz et al. Facial erythematous annular plaques: a case of annular Demodex facial dermatitis?
BR0318166A (pt) uso de uma substáncia para detectar sgk1, kit para essa detecção, bem como composição farmacêutica que inibe ou ativa a sua expressão e/ou função
Abenza-Abildua et al. Stroke due to septic embolism resulting from Aspergillus aortitis in an immunocompetent patient
Lavy et al. Pseudallescheria boydii knee arthritis in a young immunocompetent adult two years after a compound patellar fracture
Lee et al. Brain abscess due to Pseudomonas pseudomallei
Asim Risk of invasive fungal infections and osteonecrosis of jaw in patients exposed to current therapeutic drugs for COVID-19
Hocaoglu et al. Low-back pain in geriatric patients: remember abdominal aortic aneurysm!
Li et al. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients
Tang et al. The Ellsworth-Howard test revisited
Raynham et al. Hydatid disease of the skull base: report of three cases and a literature review
El‐Baba et al. National Survey of Adult Transplant Hepatologists on the Pediatric‐to‐Adult Care Transition After Liver Transplantation: What About MedPeds?
Pezzo et al. Community-acquired, methicillin-resistant Staphylococcus aureus osteomyelitis secondary to a hematogenous source: case report and review
Raptis et al. A cutaneous cyst caused by brucellosis with a negative serological test